Nocturnal enuresis affects approximately 5 to 7 million children in the United States,
making it the most common pediatric urologic complaint encountered by primary care
physicians. Despite its prevalence, nocturnal enuresis remains incompletely understood,
which can frustrate patients, family members, and physicians. Appropriate intervention is
justified for the affected child because of the potential consequences of family stress, social
withdrawal, and poor self-esteem.
Enuresis refers to the persistence of inappropriate voiding of urine beyond the age of
anticipated bladder control (age 4 to 5 y at the latest). The development of bladder control
is a multidimensional process that requires sensory awareness of bladder fullness by the
child, capacity for storage of urine, voluntary control of the bladder sphincter, psychological
desire for control, and a positive training experience. Diurnal enuresis is involuntary
leaking of urine during waking hours. Nocturnal enuresis refers to involuntary passage of
urine during sleep and is classified as primary (no prior period of sustained dryness) or
secondary (recurrence of nighttime wetting after 6 mo or longer of dryness). Recent
urology literature describes another classification of nocturnal enuresis based on the
presence or absence of other bladder symptoms. Monosymptomatic nocturnal enuresis
(MNE) is defined as a normal void occurring at night in bed in the absence of any other
symptoms referable to the urogenital tract, and it precludes any daytime symptomatology.
It is the focus of this article. Polysymptomatic nocturnal enuresis (PNE) is bed-wetting
associated with other bladder symptoms such as urgency, frequency, instability, or voiding
dysfunction. Investigations of patients who have MNE reveal that they are clearly different
from patients who have PNE.
Epidemiology/Prevalence
The spontaneous resolution rate of nocturnal enuresis is approximately 15% per year, with
1% of teenagers at 15 years of age still wetting the bed (Fig. 1). Parents may become
concerned about nocturnal enuresis when their child reaches 5 to 6 years of age and is
preparing to enter school. Most children are not concerned until 7 to 8 years of age.
Approximately 80% to 85% of children who have nocturnal enuresis have MNE. Another
5% to 10% of cases meet the definition of PNE, with daytime wetting or other bladder
symptoms. Organic causes are responsible for nocturnal enuresis in fewer than 5% of cases.
Such organic causes must be searched for and ruled out if the history suggests their
presence. There is a slight male predominance (about 60% overall) for nocturnal enuresis.
Etiologic factors contributing to MNE include genetics, sleep arousal dysfunction, uro-
*Editorial Board. Professor of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, NC.
?Assistant Professor of Pediatrics, University of Kentucky, Chandler Medical Center, Lexington, KY.
Article urology
Pediatrics in Review Vol.22 No.12 December 2001 399
dynamics, nocturnal polyuria, psychological components,
and maturational delay. That the condition probably
is multifactorial, with various contributing factors in
any one patient, confounds attempts to base therapeutic
approaches on etiology.
Genetics
A hereditary basis for nocturnal enuresis has been suspected
for years. Studies of twins show a concordance
rate of 43% to 68% for monozygotic and 19% to 36% for
dizygotic twins. Seventy percent of children who have
enuresis have a parent who has a history of the disorder.
Studies indicate that if one parent had enuresis, the
probability of a child having it is approximately 40% to
45%. If both parents were affected, the probability of a
child having the condition increases to 70% to 77%. If
neither parent had enuresis, only 15% of offspring will
have enuresis. Chromosomes 12q, 13q, and 22 all have
been named as possible locations of a gene(s) resulting in
enuresis, but a specific mechanism for enuresis related to
a gene locus is not known.
Sleep Arousal Dysfunction
The association between the presence of a full bladder
and the sensation in the brain of a full bladder occurs in
most children by the age of 5 years, which correlates with
the normative standard in the United States for nocturnal
dryness in 85% of 5-year-olds. Concurrently, by this
age the child's pattern of several sleep/wake cycles daily,
known as multiphasic sleep, has changed to a single
period of sleep daily, known as monophasic sleep. Daytime
urination control usually occurs first, followed by
learning to arouse during sleep to the sensation of a full
bladder. Many parents report that a child who has enuresis
is more difficult to arouse from sleep than are other
children in the home, but sleep studies have not documented
a convincing association between a child's sound
sleep and a nocturnal wetting episode.
The relationship of sleep patterns with enuresis is an
area of active research. In some studies, the enuretic
event seemed to occur during nonREM sleep and could
occur during any part of the night. In others, enuresis
reportedly was caused by a mild disturbance in arousal,
based on the finding that activation of the arousal center
proceeded correctly, but the transition from light sleep
to complete awakening was not achieved properly. In a
subset of patients, the arousal center in the brain failed to
activate, despite proper full bladder sensation. There is
conflicting evidence that children who have enuresis may
exhibit other parasomnias, such as sleepwalking and
night terrors. A recurrent theme in sleep research is the
child's inability to recognize the sensation of a full bladder
during sleep and failure to awaken from sleep to
urinate in an appropriate place. There appears to be a
maturational pattern of progressive central nervous system
"recognition" of bladder fullness and control over
the micturition reflex.
Urodynamics
Some children who have enuresis may have a small bladder
capacity. Functional bladder capacity in children may
be estimated by the formula: age in years plus 2, which
gives bladder capacity in ounces. By adolescence, this no
longer applies; adult bladder capacity is approximately
10 to 15 oz. Children who have small bladder capacities
probably represent a subgroup of patients who have MNE
and presumably cannot hold the normal amount of urine
produced at night. They are more likely to report frequent
daytime voiding, some nights with multiple episodes of
enuresis per night, and no history of attaining dryness.
In some children who have normal bladder capacities,
urgency may play a role in nocturnal enuresis. These
children exhibit daytime urgency, but they can maintain
bladder control during the day. They have a pattern of
partial emptying of the bladder that results in frequent
daytime urination to maintain continence and enuresis
occurring at night when they cannot void as often. No
evidence supports abnormal urodynamics in children
who have MNE. Involuntary nighttime voiding in those
who have MNE occurs with a urodynamically normal
bladder at functional capacity. Because most patients
who have abnormal urodynamics as an underlying cause
for their nighttime enuresis also have daytime symptoms,
asking patients about daytime voiding patterns in the
initial history is important.
Nocturnal Polyuria
Polyuria is defined as excessive urine production. It may
be associated with chronic illnesses such as diabetes mel-
Figure 1. Prevalence of enuresis by age.
urology enuresis
400 Pediatrics in Review Vol.22 No.12 December 2001
litus and diabetes insipidus. Caffeine, alcohol, and medications
also may cause it. Factors such as irregular food
and drink intake and staying up late also may contribute.
It seems reasonable to limit fluid intake several hours
prior to bedtime because the most common cause of
polyuria is habit polydipsia.
Since first described in 1985, the theory that MNE is
due to nocturnal polyuria with relative nocturnal deficiency
of pituitary-produced antidiuretic hormone
(ADH) has been controversial. Early studies reported
that the plasma level of ADH did not increase during
sleep in those who had enuresis compared with a rise in
ADH among unaffected children, resulting in relative
nocturnal polyuria as a factor in enuresis. Studies documenting
the percentage of children who have enuresis
and lack a nocturnal surge in ADH ranges from 25% to
100%, suggesting the presence of other factors. New
research about polyuria and enuresis theorizes that a full
bladder might communicate with the kidneys to reduce
urine production. Some recent investigations also suggest
abnormal osmoregulatory function in the kidney,
with higher solute excretion among those who have
enuresis.
Psychological Factors
Most children who have enuresis have no psychological
disorder. The dated concept that enuresis frequently is
due to anxiety or stress is unproven. On the contrary,
enuresis creates psychosocial problems for the bedwetting
child, including poor self-esteem, family stress,
and social isolation. Secondary enuresis commonly has
been attributed to psychological factors. Recent studies
show no major psychological differences between children
who have secondary enuresis and children who have
no enuresis. If a child reverts to bed-wetting during
treatment for enuresis or has increased episodes of bedwetting
during times of stress, it is more likely due to
poor compliance with treatment. Children who have
enuresis not only have lower self-esteem than unaffected
children, but they have lower self-esteem than children
who have chronic, debilitating illnesses. These study
results both emphasize the profound impact that enuresis
may have and justify a careful evaluation of psychosocial
symptoms in the family and the patient.
Maturational Delay
The fact that most children who have enuresis become
dry in time with or without intervention supports maturational
delay as a factor in MNE. At age 5 years, 15% of
children occasionally wet the bed compared with only
10% at 6 years of age. Perhaps development of central
nervous system recognition of and response to the sensation
of a full bladder is delayed, a
concept that correlates strongly with the
arousal dysfunction theory. Proposed
abnormal urodynamic factors also may
normalize as the child becomes older.
A similar process of maturation over
time is seen in other milestones of normal
development, such as the age range
of 9 to 15 months at which a child
begins to walk. Maturational delay may
be the most plausible and unifying concept among proposed
etiologic factors in MNE.
Evaluation
History
In addition to a detailed toilet training history, a family
history of enuresis should be sought because it rarely is
volunteered, even when known by a parent. Other pertinent
details of a history include the onset and pattern of
wetting, voiding behavior, sleep pattern, parasomnias,
medical conditions, daytime urinary symptoms, bowel
habits, and psychosocial factors. It also is important to
assess both the family's and the patient's attitude toward
the bed-wetting and their readiness to initiate and continue
treatment. Questions about voiding patterns may
reveal urgency or a history of small, frequent voids that
suggests bladder instability or small bladder capacity.
Organic causes of enuresis may be apparent by a history
of dysuria (urinary tract infection), polyuria and polydipsia
(diabetes insipidus or mellitus), encopresis (constipation),
abnormal urine stream (lower obstructive lesions),
gait disturbances (spinal cord pathology), or nighttime
snoring (adenoidal hypertrophy). A thorough and
thoughtful history is the means by which the infrequent
organic causes of enuresis are separated from the majority
of cases that have no organic etiology (Table).
Physical Examination
Most children who have nocturnal enuresis will have
normal findings on physical examination. In addition to
A history of small, frequent voids suggests
bladder instability or a small bladder
capacity.
urology enuresis
Pediatrics in Review Vol.22 No.12 December 2001 401
assessing the child's height, weight, and blood pressure,
perform a complete examination, paying careful attention
to the urogenital, neurologic, and gastrointestinal
systems. A palpable bladder or palpable stool may be
present on abdominal examination, ectopic ureter or
signs of sexual abuse on urogenital examination, or abnormal
gait apparent during neurologic examination.
Cremasteric, anal, abdominal, and deep tendon reflexes
that reflect spinal cord function all should be tested. The
skin of the lower back should be inspected for the presence
of a sacral dimple, hair patches, or vascular birthmarks,
which can be clues to spinal dysraphism. Mouth
breathing may suggest sleep apnea with associated enuresis
due to adenoidal hypertrophy. Direct observation of
the urinary stream in the office is important, especially if
findings on the history suggest an abnormality. The
family can measure bladder capacity at home prior to the
initial evaluation or it can be measured in the office by
having the child drink 12 oz of fluid on arrival, then
voiding into a calibrated cup.
Laboratory/Imaging Studies
All children who have enuresis should have urinalysis of a
clean-catch midstream urine specimen (Fig 2). The ability
to concentrate urine to 1.015 or greater rules out
diabetes insipidus and the absence of glucose rules out
diabetes mellitus as causes of nocturnal enuresis. Further
laboratory testing is unnecessary for MNE. A urine culture
should be obtained for symptoms suggestive of
urinary tract infection on history or findings on urinalysis.
Routine radiologic or ultrasonographic imaging
studies of the urinary tract or cystoscopy are not recommended
for children who have MNE. PNE may require
further evaluation with voiding cystourethrography
(VCUG), renal and bladder ultrasonography, or urodynamic
testing. When enuresis is resistant to treatment
and the history suggests a sleep disorder, a sleep study
may be useful to look for sleep apnea or parasomnias.
Treatment
An important factor in any pediatric treatment is the
child's motivation and acceptance. Parents also must
support the child and the treatment program for maximal
effectiveness. The child's age is a critical factor when
formulating a treatment plan. Consideration of treatment
is guided by the clinician's understanding of the
changing prevalence of enuresis in school-age children
and the effect of enuresis on the child's self-esteem and
family function. Timing of the intervention should be
tailored to the individual child and family.
Although a child's self-esteem can be harmed by
MNE, even at early school age, the effects are variable.
Table. Important Points of
a History
Urinary history
Behavioral history
? Drinking habits
? Parasomnias
? Psychiatric symptoms
? Environment
Voiding history
? Nighttime wetting and toilet practices
? Daytime symptoms
? Longevity and frequency of enuresis
? Abnormalities of urine stream
History suggesting medical etiology
? Anatomic problems (posterior urethral valves,
spina bifida, ectopic ureter)
? Diabetes insipidus
? Diabetes mellitus
? Encopresis or constipation
? Endocrine dysfunction
? Allergies or asthma
? Sleep apnea (heavy snoring or mouth breathing)
? Urinary tract infection
? Child abuse
? Urethral, genital, or midline skin abnormalities
Adapted from Faber SH, Goblin AZ, Jacobs TH, et al. Enuresis control
in primary care. Proceedings from a Symposium on the Control of Uncomplicated
Primary Nocturnal Enuresis. 1996.
Figure 2. Algorithm for evaluation and treatment of nocturnal
enuresis. Adapted from Faber SH, Goblin AZ, Jacobs TH, et
al. Enuresis control in primary care. Proceedings from a
Symposium on the Control of Uncomplicated Primary Nocturnal
Enuresis. 1966.
urology enuresis
402 Pediatrics in Review Vol.22 No.12 December 2001
Some school-age children and their parents are not bothered
by the child's enuresis; others experience anxiety
and stress. It is reasonable to discuss MNE during a
health supervision visit and provide facts for families of
patients at 6 or 7 years of age. The maturational aspects
of nighttime awakening to void should be explained to
parents and likened to other familiar developmental
milestones that occur over a range of time rather than at
a specific age. Providing plausible medical explanations,
identifying a family history of enuresis, and defining its
age-specific prevalence may lessen the burden on the
child. Parents should understand that punishment or
negative reinforcement is counterproductive, both in
resolving the enuresis and in protecting the child's selfesteem.
For children and families who are bothered by
the child's enuresis, targeted intervention is recommended
by age 8 years at the latest. In general, MNE
should be thoroughly explained, selectively treated, and
never ignored.
Nonpharmacologic Therapy
MOTIVATIONAL THERAPY. This approach begins with
educating parents and the child about enuresis, a process
that usually allays guilt. Handouts with printed instructions
can teach the parents and the child to manage the
condition. Positive reinforcement can be initiated by
setting up a diary or chart to monitor progress and
establishing a system to reward the child for each night
that he or she is dry. The child should be taken out of
diapers or training pants and encouraged to empty the
bladder completely prior to going to bed. The child
should participate in morning cleanup as a natural, nonpunitive
consequence of wetting. The risk of secondary
psychological injury to the child's self-esteem is minimized
by discouraging ridicule from siblings and by
avoiding a critical, demoralizing approach.
Because excessive fluid intake before bedtime can
cause increased nocturnal urine production, as can caffeinated
beverages and certain foods (eg, dairy products,
citrus juices, chocolate), restricting fluids for 2 hours
prior to bedtime is reasonable. The child should agree to
fluid restriction, however, rather than having it imposed.
The rate of complete resolution of enuresis with motivational
therapy alone is estimated to be only 25%, but up
to 70% of children who have MNE have some reduction
in the number of wet nights. Once consistently dry
nights are achieved, the reported relapse rate is low.
Motivational therapy is a reasonable first-line approach,
especially with the younger child. If unsuccessful after a
trial of 3 to 6 months, a different treatment program
should be considered.
BEHAVIORAL THERAPY. This approach includes drybed
training and classic conditioning therapy using an
enuresis alarm system. Hypnotherapy also may be part of
a comprehensive program to treat enuresis. This therapy
involves an age-appropriate explanation of how the brain
and bladder communicate, taking the mystery out of
enuresis by educating the patient and family, teaching
relaxation techniques, and having the child practice imagery
of awakening to urinate in the toilet or staying dry
all night. It can be combined with an alarm system.
Frequent office visits are required initially until the physician
is certain that the child can practice
imagery at home; then, visits may be
monthly. Referral to a behavioral pediatrician
or clinic may be necessary if the
primary care physician does not have the
necessary training or time for this approach.
Dry-bed training (as described by
Azrin and Thienes in 1978) involves waking the child on
a progressive schedule at decreasing intervals over several
nights, having the child change pajamas and bedding if
wet or walk to the toilet when voiding is needed. As in
the use of alarm therapy, the eventual goal is to have the
child self-awaken to void. Although a high cure rate is
reported with this technique by the authors, it is a more
time- and labor-intensive process than most families are
willing to undertake.
Enuresis alarms have the highest overall cure rate of
any available treatment. They also represent the bestresearched
behavioral intervention. Alarm systems can be
used in combination with motivational and other behavioral
therapy techniques or in combination with pharmacotherapy.
Several different alarm devices range in cost
from $50 to $75. Insurance companies may cover an
enuresis alarm with a prescription from the physician
describing it as a medical device. In contrast to the older
bell-and-pad type of alarms, the new devices are portable,
small, and worn directly on the child's clothing. They
emit a transistorized audio or vibratory alarm when urine
is sensed in the underpants.
Alarms are most effective when combined with other
behavioral or pharmacologic therapy. The alarm wakes
Enuresis alarms have the highest
overall cure rate of any available treatment.
urology enuresis
Pediatrics in Review Vol.22 No.12 December 2001 403
the child or parent from sleep, who then implements the
appropriate component of the behavioral program. The
alarm allows the parent and child to intervene and monitors
bed-wetting as the program proceeds. Parents and
child should be told that this treatment requires a longterm
commitment and may take several months to
achieve a cure. The device can be discontinued when the
child has had three consecutive weeks of dry nights. The
cure rate may be as high as 70% long-term. Among the
10% to 15% of children who relapse, most can be treated
successfully with a repeat of the original alarm program.
Methods to reduce alarm failure include pretesting
the child for his or her ability to awaken to the alarm and
encouraging parents and child to continue using the
alarm. Failure also can be reduced by enabling the child
who is afraid of the dark to walk to the toilet using a
flashlight or night light in the room or by offering other
options to the child who is reluctant to try an enuresis
alarm. If a child does not awaken to the alarm during
pretesting, dry-bed training or parent awakening should
precede the use of the alarm. One study showed that an
ordinary alarm clock used with dry-bed training was as
effective as an enuresis alarm. This may be an attractive
alternative to families who cannot afford an alarm or
whose insurance will not cover it. (See the 1997 Pediatrics
in Review article by Schmitt for practical tips on
successful use of the enuresis alarm.)
Pharmacotherapy
Medication is an attractive treatment modality for parents
who hope for relatively effortless success. However,
medication alone for initial treatment of nocturnal enuresis
is never preferred and seldom should be considered
before 8 years of age, even in combination therapy. Three
drugs are used most commonly for the treatment of
enuresis: imipramine, desmopressin (DDAVP), and oxybutynin.
Imipramine and DDAVP have been evaluated
in the treatment of MNE; oxybutynin is used primarily in
polysymptomatic enuresis.
IMIPRAMINE. Imipramine is a tricyclic antidepressant
that has been used for more than 3 decades to treat
nocturnal enuresis. It appears to increase bladder capacity
through a weak anticholinergic effect and also may
decrease detrusor muscle contractions via noradrenergic
effects. The starting dose is 25 mg taken 1 hour before
bedtime for children ages 6 to 8 years and 50 to 75 mg
for older children and adolescents. The duration of action
is 8 to 12 hours. The dose may be increased in
25-mg increments weekly up to 75 mg. Therapy may
continue from 3 to 9 months, with a slow tapering of
medication recommended over 3 to 4 weeks in 25-mg
decrements. Imipramine is relatively inexpensive, and the
clinical response is usually apparent during the first week
of treatment. The initial success rate (dry at 6 months
posttreatment) is reported to be 15% to 50%, but the
relapse rate is high following drug discontinuation.
When used at the recommended dosage, mild side
effects include irritability, dry mouth, decreased appetite,
headaches, and sleep disturbances. An accidental or intentional
overdose, however, can have serious and potentially
lethal effects, including ventricular dysrhythmias,
seizures, and coma. Because of its narrow toxic/
therapeutic ratio, some clinicians are understandably reluctant
to use imipramine to treat a relatively benign,
self-limiting condition such as nocturnal enuresis. If
imipramine therapy is selected, the physician must counsel
the family carefully about the dangerous potential of
its accidental ingestion, safe storage of the drug, and
supervision of the child taking the medication.
DDAVP. DDAVP is a synthetic analog of arginine
vasopressin (ADH). Acting on the distal tubules of the
kidney, it increases water reabsorption in the collecting
ducts, producing a more concentrated, lower volume of
urine. The use of DDAVP to treat nocturnal enuresis is
based on the observation that some children who have
enuresis do not have the normal nocturnal rise in ADH
production, potentially leading to polyuria. DDAVP theoretically
reduces urine volume at night in such children,
who thereby can avoid a full bladder at night.
DDAVP is available in an oral form and a nasal spray.
The bioavailability is only 1% for the tablet and 10% for
the nasal spray. Its duration of action is extended (approximately
10 to 12 h), and it is rapidly absorbed from
the nasal mucosa. The initial dose of DDAVP is 20 mcg
or one 10-mcg puff in each nostril within 2 hours of
bedtime, regardless of the patient's age. The dose may be
increased in increments of 10 mcg every 1 or 2 weeks up
to a maximum dose of 40 mcg. The response to DDAVP
usually can be evaluated within a few days of starting
therapy. Patients may remain on medication for 3 to 6
months, then should begin a slow decrease of the dose by
10 mcg/mo. If a child remains enuretic after 6 months of
therapy, combination therapy may be considered. If oral
medication is preferred, the starting dose is 0.2 mg (one
tablet) administered 1 hour before bedtime. If there is no
response within 1 week, the dose can be titrated by
0.2 mg up to a maximum of 0.6 mg nightly.
Side effects of DDAVP are rare and include abdominal
discomfort, nausea, headache, and epistaxis. Symptomatic
hyponatremia with seizures has been reported
urology enuresis
404 Pediatrics in Review Vol.22 No.12 December 2001
very rarely, usually in the context of exceeding the recommended
dosage. Nonetheless, nighttime fluid restriction
is a reasonable recommendation for those receiving
DDAVP. Contraindications include habit polydipsia, hypertension,
and heart disease. There are few data on
long-term use of DDAVP. In a Swedish study that monitored
children who had MNE, 22% became dry with
DDAVP, a response not significantly different from the
spontaneous cure rate of 15% per year. All patients,
however, had a marked reduction in the number of
enuretic events per month. More patients remained dry
after slow tapering of the DDAVP dose than following
abrupt discontinuation of the medicine. Various studies
show immediate response rates as high as 70% and relapse
rates as high as 95%. Moffat et al reviewed 18 controlled
studies of DDAVP and found overall that only 25% of
children were completely dry on the medicine, with a
relapse rate similar to that noted previously.
DDAVP's high initial response rate is attractive for
episodic use to treat enuresis, alone or in combination
with other treatments. It can be very useful for summer
camp and sleepovers to prevent enuresis. DDAVP also
may be useful to bridge the gap between enuresis and
dryness during other treatments. Using DDAVP episodically
also reduces its rather significant cost, which may be
$150 to $250 for 1 month of nightly use.
OXYBUTYNIN. Oxybutynin chloride is an anticholinergic
and antispasmodic drug that has a role in reducing
uninhibited bladder contractions. It is used primarily to
treat children who have symptoms of daytime urgency or
frequency in addition to nighttime enuresis. It appears to
be no better than placebo in treating children who have
MNE. Side effects are related to the anticholinergic
action of the drug and include flushing, blurred vision,
constipation, tremor, and decreased ability to sweat. The
recommended starting dose is 5 to 10 mg/d (or 0.1 mg/
kg) for most children. This drug is not approved by the
United States Food and Drug Administration to treat
enuresis in children younger than 5 years of age. Hyoscyamine
is another anticholinergic agent used to treat
bladder instability that recently has received attention in
clinical studies on enuresis. These medications may play a
role in the treatment of PNE.
Age-related Treatments
As a condition that has no single etiology and various
causal factors in any one patient, it is not surprising that
a single method of treating nocturnal
enuresis is often of limited success. Agerelated
strategies that combine more
than one treatment may improve response
rates.
Younger Than Age 8 Years
For young children and their parents,
reassurance and education about enuresis
are of utmost importance. They must
understand that nocturnal wetting is
not the child's fault. There is no place
for ridicule or a punitive approach to the
problem by parents, siblings, or peers.
Previously described motivational and behavioral methods
that assist the child in waking to void and that praise
successful dryness suit this age group best.
Ages 8 Through 11 Years
For children who still have nocturnal enuresis at this age
and for whom the child and family request an intervention,
the enuresis alarm gives the best results in terms of
response rate and low relapse rate. This also is the age at
which intermittent use of medication such as DDAVP
can be useful for special events such as an overnight at a
friend's home or a camping trip.
Ages 12 Years and Older
Because of the emotional impact of persistent bedwetting
in adolescence, aggressive intervention is indicated.
If use of an enuresis alarm does not stop or greatly
reduce the wetting episodes, continuous use of medication
is justified as additional treatment. When 2 months
of dryness using the combination of alarm and medication
are achieved, the medication should be tapered
gradually while continuing to use the enuresis alarm.
DDAVP reduces urine volume at
night and is available in an oral form
and nasal spray. Used episodically (for
summer camp, sleepovers, or to bridge the
gap during other treatments) reduces
its significant costs.
urology enuresis
Pediatrics in Review Vol.22 No.12 December 2001 405
Comparative Evaluation of Therapies
Assessments of treatment results of enuresis must consider
the rate of initial response, the duration of response,
and the relapse rate. In general, studies comparing an
alarm system with placebo or drug therapy show the
alarm system to have the most favorable combination of
initial response rate (60% to 70%) and relapse rate (10%
to 30%), especially when dryness is assessed at 12 months
after initiating treatment. The success rate with alarms, of
course, depends on continued use of the alarm. A significant
number of families (30% to 50%) discontinue use of
the alarm within only 2 to 3 weeks. Studies evaluating
medication alone compared with placebo show favorable
initial response (10% to 60%), but a significant relapse
rate (80% to 90%) when the child is off medication. Two
studies documented identical rates of 56% of children
maintaining dryness after 12 months' use of an alarm
system. In both studies, the rate of dryness after 12
months when using medication alone, either imipramine
or DDAVP, was no better than the expected improvement
rate of about 15% with no treatment.
Summary
Nocturnal enuresis is a common problem seen by the
primary care physician. It remains a source of considerable
anxiety for the child, parents, and sometimes the
pediatrician. In spite of several decades of research, no
single explanation or classification of enuresis is sufficient.
The nocturnal wetting episode occurs when the
child does not awaken during sleep at a time when urine
volume exceeds functional bladder capacity, due either
to excess urine production, small bladder capacity, or
both. This perspective requires the practitioner to take a
careful history for polyuria, sleep dysfunction, and daytime
bladder symptoms to devise the best treatment for
each child. Once organic causes are ruled out by careful
history and physical examination, no laboratory or radiographic
evaluation is necessary beyond a simple urinalysis.
Although a spontaneous cure rate of 15% per year can
be expected, intervention may benefit some children
through earlier attained dryness and improved selfesteem.
Behavior therapies, including alarm systems,
have the best long-term results, but they require strong
family commitment and do not offer immediate results.
Medication has a better short-term cure rate than
motivational/behavioral therapy, but relapse rates are
high when drugs are discontinued. A combination of
behavioral therapy and pharmacotherapy is reasonable if
monotherapy fails. The ultimate goal is for the child to
maintain nighttime dryness or to self-awaken to void at
night.
Suggested Reading
Azrin NH, Thienes PM. Rapid elimination of enuresis by intensive
learning without a conditioning apparatus. Behav Ther. 1978;9:
342-354
Chandra M. Nocturnal enuresis in children. Curr Opin Pediatr.
1998;10:167-173
Djurhuus JC, Rittig S. Current trends, diagnosis, and treatment of
enuresis. Eur Urol. 1998;33(supplement 3):30-33
Faber SH, Goblin AZ, Jacobs TH, et al. Enuresis control in primary
care. Proceedings from a Symposium on the Control of Uncomplicated
Primary Nocturnal Enuresis. 1996
Hjalmas K. Nocturnal enuresis: basic facts and new horizons. Eur
Urol. 1998;33(supplement):53-57
Mellon MW, McGrath ML. Empirically supported treatments in
pediatric psychology: nocturnal enuresis. J Pediatr Psychol.
2000;25:193-214
Moffatt ME. Nocturnal enuresis: a review of the efficacy of treatments
and practical advice for clinicians. J Dev Behav Pediatr.
1997;18:49
Moffatt ME, Kato C, Pless IB. Improvement in self-concept after
treatment of nocturnal enuresis: a randomized clinical trial.
J Pediatr. 1987;110:647
Monda JM, Husmann DA. Primary nocturnal enuresis: a comparison
among observation, imipramine, desmopressin acetate and
bed-wetting alarm systems. J Urol. 1995;154:745-748
Neveus T, Stenberg A, Lackgren G, et al. Sleep of children with
enuresis: a polysomnographic study. Pediatrics. 1999;103:
1193-1197
Olness K. The use of self-hypnosis in the treatment of childhood
nocturnal enuresis: a report of forty patients. Clin Pediatr.
1975;14:273-279
Robson WLM. Diurnal enuresis. Pediatr Rev. 1997;18:407-412
Schmitt BD. Nocturnal enuresis. Pediatr Rev. 1997;18:183-191
Scmitt BD. Nocturnal enuresis: finding the treatment that fits the
child. Contemp Pediatr. 1990;7:70
Schulman SL, Colish Y, vonZuben FC, et al. Effectiveness of
treatment for nocturnal enuresis in a heterogeneous population.
Clin Pediatr. 2000;39:359-364
Tietjen DN, Husmann DA. Nocturnal enuresis: a guide to evaluation
and treatment. Mayo Clin Proc. 1996;71:857-862
urology enuresis
406 Pediatrics in Review Vol.22 No.12 December 2001
PIR Quiz
Quiz also available online at www.pedsinreview.org.
1. The likelihood of enuresis occurring in a child whose parents both had enuresis is closest to:
A. 75%.
B. 50%.
C. 25%.
D. 10%.
E. 5%.
2. Of the following statements about the impact of anxiety or stress on regressive bed-wetting, the most
accurate is that:
A. Children who have chronic, debilitating illnesses are more prone to enuresis than those who do not have
such illnesses.
B. Children whose families are in stressful situations, such as with family finances, are more prone to
enuresis than other children.
C. Enuresis is more common among ethnic minorities.
D. Poor self-esteem has been shown to correlate with enuresis.
E. The causative association between enuresis and anxiety or stress is not proven.
3. Of the following, the etiologic factor that may be the most plausible explanation for enuresis beyond the
age at which it usually ceases is:
A. Maturational delay.
B. Nocturnal polyuria due to chronic illness.
C. Psychological factors.
D. Sleep arousal dysfunction.
E. Small bladder capacity.
4. Motivational therapy results in complete regression of enuresis in approximately what percentage of
patients for whom it is used?
A. 5%.
B. 25%.
C. 50%.
D. 75%.
E. Almost 100%.
5. The cure rate for enuresis using alarms is up to:
A. 10%.
B. 30%.
C. 50%.
D. 70%.
E. 90%.
6. Pharmacotherapy generally should not be employed as sole treatment for enuresis in patients younger than
age:
A. 3 years.
B. 4 years.
C. 5 years.
D. 8 years.
E. 15 years.
urology enuresis
Pediatrics in Review Vol.22 No.12 December 2001 407